Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content +++ DEFINITION AND CLASSIFICATION ++ The marginal zone lymphomas (MZLs) are derived from memory-type or antigen-experienced B cells that reside in regions contiguous to the outer part of the mantle zones of B-cell follicles MZL cells are usually small to medium-sized lymphocytes with irregularly shaped nuclei with dispersed chromatin and inconspicuous nucleoli. The World Health Organization (WHO) defines three separate MZL entities, namely, the extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (known as MALT lymphoma) (70%), the splenic marginal zone B-cell lymphoma (SMZL) (20%), and the nodal marginal zone B-cell lymphoma (NMZL) (<10%). Lymphoepithelial lesions characterized by invasion or necrotic destruction of the glandular epithelium by infiltrating lymphoma cells are characteristic of MALT lymphomas, especially those affecting the stomach. The WHO also recognize three provisional entities: — Extranodal marginal zone lymphoma (EMZL) of the MALT type. — Splenic marginal zone lymphoma (SMZL). — Nodal marginal zone lymphoma (NMZL). +++ EPIDEMIOLOGY ++ MZLs account for about 10% of all non-Hodgkin lymphomas in the United States and Western Europe. There is a slight female predominance. Median age of presentation is about 60 years. +++ PATHOPHYSIOLOGY ++ MALT lymphomas arise from mucosa-associated lymphoid tissues in the context of chronic inflammation. Gastric MALT lymphoma is one of the best examples of a microbiologic (Helicobacter pylori) cause of a human malignancy. In addition to H pylori, other bacteria are probably implicated in the pathogenesis of MZLs arising in the skin (Borrelia burgdorferi), in the ocular adnexa (Chlamydophila psittaci), and in the small intestine (Campylobacter jejuni). Hepatitis C virus (HCV) may be involved in the pathogenesis of several types of MZL. There is great geographic variation in the strength of these associations that is not satisfactorily explained. An increased risk of developing MALT lymphoma has also been reported in individuals affected by autoimmune disorders, especially Sjögren syndrome and systemic lupus erythematosus. Several recurrent chromosomal translocations have been described in extranodal MZLs. Three of them—[t(11;18)(q21;q21), t(1;14)(p22;q32), and t(14;18)(q32;q21)]—are the best characterized; they each affect the same signaling pathway, activating nuclear factor-kappa B (NF-κB), a transcription factor that plays a major role in immunity, inflammation, and apoptosis (Table 64–1). ++Table Graphic Jump LocationTABLE 64–1COMMON GENETIC LESIONS IN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMAView Table||Download (.pdf) TABLE 64–1 COMMON GENETIC LESIONS IN MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA Lesion Genes Frequency Sites Translocations t(11;18)(q21;q21) t(14;18)(q32;q21) t(1;14)(p22;q32) t(3;14)(p13;q32) BIRC3-MALT1 IGHV-MALT1 IGHV-BCL10 IGHV-FOXP1 15%–40% 20% <5% <5% Stomach, lung Lung, skin, ocular adnexa, salivary gland Stomach, lung Unclear Gains +3; +3q +18; +18q 20%–40% 20%–40% No differences in sites No differences in sites Losses –6q23 TNFAIP3 15%–30% No differences in sites BCL-10, B-cell CLL/lymphoma 10 gene; BIRC3, baculoviral IAP repeat-containing 3 gene; FOXP1, forkhead box P1 gene; IGHV, immunoglobulin heavy-chain variable region gene; MALT1, mucosa-associated lymphoid tissue translocation gene ... Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.